What are the clinical signs that a person is taking a GLP‑1 receptor agonist?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Signs of GLP-1 Receptor Agonist Use

The most reliable clinical signs that someone is taking a GLP-1 receptor agonist are significant progressive weight loss (6-20% of body weight), gastrointestinal symptoms (particularly nausea and early satiety), and visible subcutaneous injection sites on the abdomen, thigh, or upper arm.

Primary Observable Signs

Weight Loss Pattern

  • Substantial and sustained weight reduction is the hallmark sign, with non-diabetic patients losing 6.1-17.4% of body weight and diabetic patients losing 4-6.2% 1
  • Semaglutide produces approximately 14.9% mean weight loss, while tirzepatide can achieve up to 20.9% reduction at higher doses 1
  • This degree of weight loss was previously only achievable with bariatric surgery 1

Gastrointestinal Manifestations

The most common and recognizable signs include 1:

  • Nausea and vomiting (most frequent adverse effect)
  • Early satiety and reduced appetite
  • Dyspepsia and gastroesophageal reflux
  • Diarrhea or constipation
  • Abdominal bloating

These symptoms are dose-dependent and more pronounced with short-acting agents (exenatide, liraglutide) compared to long-acting formulations 1. Symptoms typically appear or worsen following dose escalation 2.

Physical Examination Findings

  • Subcutaneous injection sites: Look for evidence of regular injections on the abdomen, anterior/lateral thigh, or upper arm
  • Recent significant weight loss: Loose skin, changes in clothing fit, temporal wasting
  • Signs of delayed gastric emptying: Postprandial fullness, visible gastric distension on examination

Secondary Clinical Indicators

Altered Eating Behavior

  • Patients may report that food tastes different, is less enjoyable, or less tempting 3
  • Reduced portion sizes and meal frequency
  • Changes in food preferences (often away from high-fat foods) 1

Cardiovascular Signs

  • Mild tachycardia may be present (small increases in heart rate of unknown clinical significance) 4
  • Improved blood pressure readings if previously hypertensive 4

Laryngeal Symptoms (Emerging Evidence)

Recent data suggests increased risk of 5:

  • Persistent cough (OR 1.46)
  • Voice and resonance disorders (OR 1.19)
  • Foreign body sensation in throat (OR 1.41)

Medication-Specific Clues

Common GLP-1RA Agents

Patients may be using 6:

  • Semaglutide (Ozempic, Wegovy): Weekly subcutaneous injection
  • Liraglutide (Victoza, Saxenda): Daily subcutaneous injection
  • Dulaglutide (Trulicity): Weekly subcutaneous injection
  • Tirzepatide (Mounjaro, Zepbound): Weekly subcutaneous injection (dual GLP-1/GIP agonist)
  • Exenatide (Byetta, Bydureon): Twice daily or weekly formulations

Critical Clinical Context

Gastroparesis Risk

Be particularly alert for signs of gastroparesis 2:

  • Persistent nausea and vomiting despite appropriate dosing
  • Severe early satiety and oral intolerance
  • Symptoms appearing hours to months after initiation, especially following dose escalation
  • Gastric distension on imaging or retained gastric contents

Peri-operative Implications

If surgery is planned, these patients have 6:

  • Delayed gastric emptying confirmed by multiple modalities (endoscopy, ultrasound, scintigraphy)
  • Increased risk of residual gastric content despite appropriate fasting
  • Potential need for modified anesthetic approach

Common Pitfalls

  1. Don't assume all weight loss is intentional: Some patients may not disclose GLP-1RA use, particularly if obtained through non-traditional channels
  2. Don't dismiss GI symptoms as unrelated: These are the most common adverse effects and may indicate recent dose escalation 7
  3. Don't overlook injection sites: Regular subcutaneous injections leave subtle but identifiable marks
  4. Don't confuse with eating disorders: The altered eating experience is pharmacologically mediated, not psychological 3

Diagnostic Confirmation

When GLP-1RA use is suspected but not disclosed:

  • Direct questioning about diabetes or weight loss medications
  • Review of prescription records and pharmacy data
  • Examination for injection site evidence
  • Assessment of temporal relationship between weight loss and symptom onset
  • Point-of-care gastric ultrasound if peri-operative concerns exist 6

The combination of significant weight loss, characteristic GI symptoms, and injection site evidence provides high clinical certainty of GLP-1RA use, even without patient disclosure.

References

Related Questions

Should I stop gliclazide when starting a GLP‑1 receptor agonist?
What are the recommended initiation and titration protocols, contraindications, and monitoring considerations for GLP‑1 receptor agonist therapy in patients with diabetes?
How to manage body aches in patients taking Glucagon-like peptide-1 (GLP-1) receptor agonist medications?
Can someone taking duloxetine and Remeron (mirtazapine) take GLP-1 (Glucagon-like peptide-1) receptor agonists?
How should I manage a female patient who experiences nausea and vomiting during bowel movements while on a GLP‑1 receptor agonist (e.g., liraglutide) and taking polyethylene glycol (Miralax)?
Can a patient with infectious mononucleosis safely take ibuprofen (nonsteroidal anti-inflammatory drug) for fever, sore throat, and muscle aches if there are no contraindications such as renal disease, gastrointestinal ulcer, uncontrolled asthma, or NSAID allergy?
How should I obtain a focused history for a patient with facial angioedema and pruritus?
What is the normal urine color in newborns and infants, and what abnormal colors indicate possible pathology?
Is metronidazole (Metrogyl) appropriate for treating acute calculous cholecystitis compared to rifaximin?
What are the possible causes and recommended workup for a patient who can recognize a face but cannot recall the person's name?
What is the term for the condition in which a person can recognize a familiar face but cannot retrieve the individual's name?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.